KR20110035090A - Implantable tube and coating method of the same - Google Patents

Abstract

PURPOSE: A tube for transplant and a coating method thereof are provided to promote bonding of the peripheral tissue and a transplanted structure. CONSTITUTION: A tube(10) for transplant includes bio-active material which is coated on a structure having lumen. The bio active material includes a material which promotes bonding of a structure transplanted into the human body and peripheral tissue. The material promoting boding is a material promoting generation of a blood vessel.

Description

Implantable tube and its coating method {IMPLANTABLE TUBE AND COATING METHOD OF THE SAME}

The present invention relates to an implantable tube and its coating method that is implanted and used as a circulation passage of the human body.

In general, hemodialysis is a dialysis therapy used for end-stage renal convertors, which removes nitrogen-containing waste from the patient's blood, and circulates some of the patient's blood with a dialysis machine (artificial kidney) to relieve major renal function. It is on behalf of.

In order to perform such hemodialysis, a passage for dialysis treatment must be created in the blood vessel, and a place should be installed in the vein side to draw arterial blood from the patient, connect it to the artificial kidney, and return the dialysis blood back to the patient.

Here, blood can be taken in and out of the external shunt method using a scrub nut with a cannula made of plastic inserted into the intravenous vein, and the diaphragm with the anastomosis of the intravenous sinus. There are methods such as puncture resistance and artificial blood vessel implantation each time.

Artificial blood vessels, on the other hand, have been developed as an alternative means of guiding blood flow when a patient's blood vessels are narrowed by some factor or when their function is deteriorated, and their chemical composition, physical properties, porosity, elasticity, surface Opening rates will be affected by structural aspects.

However, when using artificial blood vessel transplantation to receive hemodialysis, blood vessels are constricted at the site connecting the artificial blood vessel and the arteriovenous vein of the patient, which causes the disruption of blood flow. As a technology for this, the inventor of the present application has developed and applied for the technology according to Korean Patent Application Publication No. 10-0596218 (tube for hemodialysis connection of hemodialysis patient whose drug is surface-treated).

This relates to a tube for arteriovenous connection of hemodialysis patients, and a technique has been proposed in which drugs are surface-treated on the inner and outer surfaces of artificial blood vessels to improve the narrowing of the connection between the tube and the arteriovenous by endothelial hyperproliferation.

On the other hand, the method using the implantation of artificial blood vessels, in addition to the problem of improving the narrowing, hemodialysis is possible after about two to four weeks of stabilization period before implanting the artificial blood vessels and starting the first dialysis. This is because the anastomosis wound of the artificial blood vessel is closed, and a certain amount of myofibroblast is propagated between the implanted artificial blood vessel and the surrounding tissue so that the artificial blood vessel is coupled to the surrounding tissue and fixed.

SUMMARY OF THE INVENTION The present invention has been made in view of the above-described problems, and an object thereof is to provide an implantable tube and a coating method thereof that can promote the implantation of the implanted structure with surrounding tissue.

In order to achieve this object, in one aspect of the present invention, the implantable tube is coated with a bioactive material on a structure having lumen, and the bioactive material is implanted into the body to be connected with surrounding tissue. It is characterized by including a substance that promotes bonding.

And the material that is implanted in the body to promote the binding to the surrounding tissue is characterized in that the material for promoting angiogenesis.

In addition, the material is implanted into the body to promote the binding to the surrounding tissues is characterized in that the substance to promote the growth of myofibroblasts.

At this time, the substance promoting the growth of the myofibroblast is characterized in that any one of Vascular Endothelial Growth Factor (VEGF), Epidermal Growth Factor (EGF), Platelet Derived Growth Factor (PDGF), and Fibroblast Growth Factor (FGF). .

Meanwhile, the bioactive material is coated on the outer surface of the structure.

And the bioactive substance is characterized in that it further comprises a drug for inhibiting neointimal hyperplasia (Neointimal Hyperplasia).

Here, the drug for inhibiting endometrial hyperproliferation is characterized in that the coating on the inner surface (內 面) of the structure.

On the other hand, the structure is characterized in that the thin film of e-PTFE (Expanded Polytetrafluoroethylene) having micropores.

In addition, the material that is implanted into the body to promote the binding to the surrounding tissue is characterized in that the production of a drug that induces the production of a material that promotes the binding to the surrounding tissue.

In this case, the drug is implanted into the body to induce the production of a substance that promotes the binding to the surrounding tissues is characterized in that the chemical drug (Chemical Drug).

Meanwhile, in order to achieve the above object, the implantable tube is coated with a bioactive material on a structure having a lumen, and the bioactive material is implanted into the body to promote binding to surrounding tissues. It is characterized in that it comprises a drug for inducing the production of the substance.

And the drug is implanted into the body to induce the production of a substance that promotes the binding to the surrounding tissues is characterized in that the chemical drug (Chemical Drug).

In addition, the tube coating method for implantation in one aspect of the present invention in order to achieve this object includes a process of coating a bioactive material on a structure having a lumen, the bioactive material is implanted in the body surrounding tissue It is characterized in that it comprises a substance that promotes bonding with.

And the material that is implanted in the body to promote the binding to the surrounding tissue is characterized in that the material for promoting angiogenesis.

On the other hand, the structure is implanted in the body material that promotes binding to the surrounding tissue is characterized in that the material to promote the growth of myofibroblasts.

In addition, the bioactive material is characterized in that the coating on the outer surface of the structure.

On the other hand, the bioactive substance is characterized in that it further comprises a drug for inhibiting neointimal hyperplasia (Neointimal Hyperplasia).

At this time, the drug that inhibits the neointimal hyperplasia is characterized in that it further comprises a process of coating on the inner surface of the structure.

And the material is implanted into the body to promote the binding to the surrounding tissue material is characterized in that it is produced by a drug that induces the production of a material that promotes the binding to the surrounding tissue.

Here, the drug is implanted into the body to induce the production of a substance that promotes the binding to the surrounding tissue is characterized in that the chemical drug.

Meanwhile, in order to achieve the above object, the tube coating method for implantation in one embodiment of the present invention includes a process of coating a bioactive material on a structure having a lumen, wherein the bioactive material is implanted into the body and surrounding tissue It is characterized in that it comprises a drug for inducing the production of a substance that promotes binding to.

At this time, the drug is implanted in the body to induce the production of a substance that promotes the binding of the tissue with the surrounding tissue, the drug tube coating method, characterized in that the chemical drag.

As described above, according to the present invention, when a structure coated with a bioactive material is implanted in the body, the effect of shortening the stabilization period until the dialysis starts by promoting the reaction in which the structure is combined with the surrounding tissues and fixed thereto is effective. have.

In addition, by coating a structure with a drug that induces the production of a substance that promotes binding to the surrounding tissue, a substance that promotes binding to the surrounding tissue is produced, so when the structure is implanted into the body, It has the effect of accelerating the settling reaction to shorten the stabilization period to start dialysis.

Moreover, the drug that induces the production of a substance that promotes binding to the surrounding tissue is a chemical drug, and it is easy to coat the structure with a drug that induces the production of the substance that promotes the binding to the surrounding tissue. There is.

The preferred embodiments of the present invention will be described in more detail with reference to the accompanying drawings, in which the technical parts already known will be omitted or compressed for simplicity of explanation.

The present invention is a structure having a lumen (Lumen) is implanted in the body is coated with a substance that promotes the binding to the surrounding tissue, in the embodiment of the present invention, the structure having a lumen artery (A) of patients with renal failure patients requiring hemodialysis ) And the example used in connection with the vein (V).

Here, lumen is used as a term referring to a lumen such as a lumen or a urethral canal in a tubular period such as a blood vessel, and in the present invention, a structure having a lumen is referred to as a tube (10). Collectively).

As shown in Figure 1, the tube 10 of the present invention is implanted in the body to be used to connect to the arteries (A) and veins (V) of patients with renal failure who need hemodialysis, in the present invention tube 10 It is possible to coat the outer surface with a substance that promotes the binding reaction between the tube 10 and the surrounding tissue so that it is well fixed to the arteries (A) and veins (V), angiogenesis and myofibroblasts (Myofibroblast) We will describe the coating of a drug that stimulates the proliferation of c) or a drug that induces the production of growth factors that promote binding to surrounding tissues.

In general, the patient undergoes a stabilization period of about 2 to 4 weeks until the patient receives the tube 10 and the first dialysis, which closes the anastomosis and the implanted tube 10 is surrounded by As a period necessary for fixation to the tissue, a period until a state in which blood vessels or nerves are in contact with each other through the internal space 13 of the tube 10 is required.

Therefore, as shown in FIG. 2, the bioactive material 15 is coated on the outer surface of the main body 11 so as to shorten the stabilization period so that the binding reaction with the surrounding tissues is promoted. Active substances include substances that promote angiogenesis, substances that promote the proliferation of myofibroblasts, and drugs that induce the production of growth factors that promote binding to surrounding tissues. At this time, the body 11 is a structure having a lumen before the bioactive material 15 is coated.

Meanwhile, substances that promote the growth of myofibroblasts include Vascular Endothelial Growth Factor (VEGF), Epidermal Growth Factor (EGF), Platelet Derived Growth Factor (PDGF), and Fibroblast Growth Factor (FGF). Other materials may be used.

At this time, VEGF is a vascular endothelial growth factor, increases the permeation of plasma proteins in capillaries, promotes cell division and migration, and has a function of inducing proteolytic enzymes causing cell reconstitution. In addition, through the inhibition of cell death to maintain the survival of newly formed blood vessels, and promote the movement of blood vessel cells to promote the development and differentiation of new cells.

EGF is a factor that promotes the growth of epithelial cells, induces cell division, promotes the growth of epithelial cells, promotes cell proliferation of fibroblasts that synthesize collagen, a component of the dermis, promotes angiogenesis of the damaged skin area, and It plays a key role in skin regeneration, such as inducing secretion of other regeneration promoters.

PDGF is a platelet-induced growth factor that helps cell division in fibrous cells, flexible muscle connective tissue, and heals and regenerates nerve tissue cells.

FGF is a heparin-coupled growth factor that promotes cell growth. It is used as a factor in promoting wound healing by promoting cell proliferation and development in the human body.

As such, materials such as VEGF, EGF, PDGF, and FGF are classified as growth factors, and it is possible to easily coat the outer surface of the body 11 using drugs that induce the production of such growth factors.

At this time, in the present invention, since the drug that induces the growth factor is a chemical drug, the drug can be easily coated on the main body 11, so that the chemical drug coated tube 10 can be implanted in the human body. have.

Meanwhile, in the embodiment of the present invention, as shown in FIG. 3, a coating layer 15 coated with a bioactive material is formed on the outer surface of the main body 11, as shown in FIG. The newly producing material 15-b is first coated and then the material 15-a which promotes the proliferation of myofibroblasts between the tube 10 and the surrounding tissue is coated, or as shown in FIG. It is possible to coat a substance 15-a which promotes the proliferation of myofibroblasts between the body 11 and the surrounding tissues, and then a substance 15-b which creates a blood vessel in the human body.

Alternatively, depending on the needs, the material 15-a for promoting the proliferation of myofibroblasts between the body 11 and the surrounding tissues and the material 15-b for producing blood vessels in the human body may be coated. . This produces a tube 10 coated on the body 11.

In addition, it is also possible to coat a drug that induces the production of growth factors to promote binding to surrounding tissue, which is coated on the outer surface of the body 11 to form a coating layer 15, which creates new blood vessels in the human body. It may also be configured to be coated with a material 15-b or a material 15-a for promoting the proliferation of myofibroblasts between surrounding tissues.

At this time, the drug to induce the growth factor can be easily and easily coated on the body 11, inducing the production of growth factors to promote the bonding with the surrounding tissues to shorten the required stabilization period after transplantation To do that.

On the other hand, as shown in Figure 4, it is also possible to coat the main body 11 with the drug 17 that suppresses endometrial hyperproliferation, which serves to suppress endointimal hyperplasia or thrombosis (Thrombosis) Because of this, edema occurs in the connection between the implanted tube 10 and the surrounding tissue or prevents a condition in which blood vessels are constricted and cannot function as an artificial blood vessel.

At this time, the substances that play a role in reducing the occurrence of such narrowing or inflammation include paclitaxel, rapamycin, taclorimus, cyclosporine A, etc. In addition, if the drug that can suppress the narrowing or inflammation of blood vessels, other substances are used. It is also possible.

Here, it is preferable to coat the drug 17 which suppresses endometrial hyperproliferation only on the inner surface of the main body 11 of the present invention, and both the outer surface and the inner surface of the main body 11 may be coated.

On the other hand, as a coating method of the drug to inhibit the endothelium hyperproliferation, it is possible to use a mixed solvent in which a substance that suppresses the endothelium hyperproliferation, the mixed solvent is to use methylene chloride or acetone which is highly volatile.

In addition, the method for producing the tube 10 by coating the body 11 of the present invention is to be coated on the outer surface of the body 11 is coated with a bioactive material that promotes bonding and fixing to the surrounding tissue, such a material In the case of this protein, use a coating method using gel or wrap.

On the other hand, it is possible to use a chemical drag, which is a drug that induces the growth factor (Growth Factor) to be more easily coated, in this case, by spray coating (spray) method to make a coating solution using an organic solvent It is possible to use, and if you want to coat the coating solution only on the outer surface of the structure, it is also possible to use a dipping (dipping) method to immerse the coating solution by blocking both ends of the structure.

Meanwhile, the tube 10 of the present invention uses a thin film of expanded polytetrafluoroethylene (e-PTFE) having micropores, which is obtained by stretching PTFE in various directions by extrusion at high temperature and high pressure, and has a very low coefficient of friction. It is also used as an artificial blood vessel because it has antithrombogenic properties such as delaying the adsorption of proteins when it comes into contact with blood, and is also used as a flexible fiber material.

In addition, the embodiment of the present invention has been described that the tube 10 is used for arteriovenous connection in patients with renal failure patients requiring hemodialysis, in the present invention, the drug-coated tube 10 is also used as an artificial lymphatic vessel connecting the lymphatic vessels. Its use is possible.

For example, the drug-coated tube 10 can be used for diseases such as Critical Limb Ischemia, and in addition to being used as a vascular access route, coronary artery bypass pass (CABG) and It can also be used as a replacement vessel.

As described above, the detailed description of the present invention has been made by the embodiments with reference to the accompanying drawings. However, since the above-described embodiments have only been described with reference to preferred examples of the present invention, the present invention is limited to the above embodiments. It should not be understood to be limited, and the scope of the present invention should be understood as the following claims and equivalent concepts.

Figure 1 shows an embodiment of the tube connecting the artery and vein of the patient for hemodialysis.

Figure 2 shows the drug is coated on the tube which is an embodiment of the present invention.

Figure 3 shows the appearance of a coating layer coated with a drug in an embodiment of the present invention tube.

Figure 4 shows the appearance of the drug coated on the inner surface of the tube in the embodiment of the present invention to inhibit endothelium hyperproliferation.

<Explanation of symbols for the main parts of the drawings>

10: tube

11: body

13: interior space

15-a: substance that promotes proliferation of myofibroblasts

15-b: Substances that create new blood vessels in the human body

17: Drugs That Inhibit Endometrial Hyperplasia

A: artery

V: vein

Claims (20)

The bioactive material is coated on the structure with lumen, The bioactive material includes a tube for implantation, characterized in that the structure is implanted in the body to promote the binding to the surrounding tissue. The method of claim 1, Implantation tube, characterized in that the implanted material in the body to promote the binding to the surrounding tissue is a material that promotes angiogenesis. The method of claim 1, Implantation tube, characterized in that the material is implanted into the body to promote the binding of the surrounding tissue is a substance that promotes the proliferation of myofibroblasts. The method of claim 3, Implants promoting the growth of the myofibroblasts are any one of: Vascular Endothelial Growth Factor (VEGF), Epidermal Growth Factor (EGF), Platelet Derived Growth Factor (PDGF), and Fibroblast Growth Factor (FGF) tube. The method of claim 1, And the bioactive material is coated on an outer surface of the structure. The method of claim 1, The bioactive substance further comprises a drug that inhibits neointimal hyperplasia. The method of claim 6, The drug for inhibiting endometrial hyperproliferation is coated on the inner surface of the structure (graft). The method of claim 1, The structure is a tube for implantation, characterized in that the thin film of e-PTFE (Expanded Polytetrafluoroethylene) having micropores. The method of claim 1, The implantable tube of claim 1, wherein the structure is implanted into the body to promote the binding to the surrounding tissue is produced by a drug that induces the production of a substance that promotes the binding to the surrounding tissue. The bioactive material is coated on the structure with lumens, The bioactive material is a implantable tube, characterized in that the structure is implanted into the body containing a drug that induces the production of a substance that promotes the binding to the surrounding tissue. The method according to any one of claims 9 to 10, The drug implanted in the body to induce the production of a substance that promotes the binding to the surrounding tissue is a drug drug, characterized in that the chemical drug (Chemical Drug). Coating the bioactive material onto the structure having lumens, The bioactive material is implantable tube coating method, characterized in that the structure is implanted in the body to promote the binding to the surrounding tissue. The method of claim 12, Transplanting tube coating method, characterized in that the material is implanted in the body to promote the binding to the surrounding tissues to promote angiogenesis. The method of claim 12, Transplantation tube coating method, characterized in that the material is implanted into the body to promote the binding of the surrounding tissue is a substance that promotes the proliferation of myofibroblasts. The method of claim 12, And the bioactive material is coated on an outer surface of the structure. The method of claim 12, The bioactive material further comprises a drug that inhibits neointimal hyperplasia. The method of claim 16, Transplantation tube coating method further comprises the step of coating the drug on the inner surface of the structure to inhibit the neointimal hyperplasia. The method of claim 12, And the material that is implanted into the body to promote binding to the surrounding tissue is produced by a drug that induces the production of a material that promotes binding to the surrounding tissue. Coating the bioactive material onto the structure having lumens, The bioactive material is implantable tube coating method characterized in that it comprises a drug that is implanted in the body to induce the production of a substance that promotes the binding to the surrounding tissue. The method according to any one of claims 18 to 19, The method of coating a tube for implantation, characterized in that the drug is implanted into the body to induce the production of a substance that promotes the binding to the surrounding tissue is a chemical drag.

Images